Pharmaceutical Technology Editors

The financial news and research organization has announced the winners of the first Biotech Innovator Awards.

Gerresheimer is showcasing its range of Duma Pocket containers, which are available in different sizes and colors and come with various closures.

The partnership and the formation of the institute intend to bring together industry, academia, and regulators to tackle challenges and provide solutions for continuous manufacturing.

CordenPharma will expand development capacity for small molecules, peptides, and carbohydrates at its Liestal, Switzerland site

The agency has published a continuity plan for its move from the United Kingdom.

Almac Group’s Almac Pod, a temperature-controlled shipping solution service for biologics and other temperature-sensitive products, is available in the United States.

DSM Sinochem Pharmaceuticals has filed a lawsuit against CSPC Pharmaceutical Group, Inner Mongolia Changsheng Pharmaceutical Company, and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) for infringement of its amoxicillin patent.

Croda is showcasing its portfolio of high-purity pharmaceutical excipients that can be used to maximize API performance.

Gerresheimer’s ready-to-fill vials will be delivered adopting Ompi EZ-fill packaging process.

The companies will collaborate to produce and improve the recombinant properties of Aethlon’s Hemopurifier blood purification device.

The Belgian biopharmaceutical company has formed a subsidiary in the United States, and appointed Daniel Schneider as its general manager.

The new center will serve as a regional hub where scientists and engineers can work with customers for biological development.

Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology.

Stelara (ustekinumab), already approved for treating adults, is now also approved for treating adolescents with moderate to severe plaque psoriasis.

The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.

The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.

Piramal is investing $55 million into the expansion of its API manufacturing capabilities and capacities across sites in North America and Asia.

Dow’s portfolio of solutions for pharmaceutical applications now includes products from Dow Corning’s silicone technology platform.

Samsung BioLogics’ second facility adds 152,000 L of mAb drug substance capacity.

Baxter and FDA are working together to prevent shortages of the company’s sodium chloride 0.9% injection bags after recent hurricanes damaged the island.

The committee has voted unanimously to approve Spark Therapeutics’ gene therapy candidate, Luxturna (voretigene neparvovec), for treating a genetically inherited blindness.

Coperion K-Tron has added the K3-PH-ML-D4-QT35 design to the company’s K3-PH line of feeders for a variety of continuous processes, and will showcase the feeder at the 2017 ISPE Annual Meeting and Expo.

West will be showcasing its range of packaging components and drug delivery solutions, including NovaPure components, LyoSeal caps, and the SmartDose platform.

Predicted areas of growth include flow chemistry, fermentation, repatriation of overseas funds, oncology, and API/product integration, but the rate of change is unclear.

The companies have entered into a strategic collaboration to establish a new cell therapy and regenerative medicine manufacturing platform, which includes a new manufacturing facility in Belgium.

The company is investing EUR 170 million (US$201 million) to expand its vaccine manufacturing site in France for its newest influenza vaccine.

Fluence Analytics’ Argen is a protein and polymer stability monitoring product that uses continuous light scattering measurements to produce an information stream.

NIH has entered a five-year, $215-million collaboration with leading biopharmaceutical companies to advance the development of cancer immunotherapies.

Investments include the installation of development and analytical equipment to support the development of highly potent APIs as well as a new 2800-liter hydrogenator and 1500-mm diameter centrifuge for increased flexibility and capacity within the manufacturing plant.

The collaboration will focus on developing a novel and differentiated challenge model for respiratory syncytial virus.